# hVIVO signs £2.5m contract for Omicron characterisation study

- Link: https://www.directorstalkinterviews.com/hvivo-signs-2.5m-contract-for-omicron-characterisation-study/4121158976
- Published: 2024-06-03T07:08:02+01:00
- Author: Amilia Stone

**[hVIVO plc](https://www.directorstalkinterviews.com/company/hvivo-plc/hvo.l) **(
[LON:HVO](https://www.directorstalkinterviews.com/company/hvivo-plc/hvo.l)), a fast
growing specialist contract research organisation (CRO) and world leader in testing
infectious and respiratory disease products using human challenge clinical trials,
has announced that it has signed a £2.5m contract with a mid-sized pharmaceutical
company to initiate an Omicron characterisation study. The manufacture of hVIVO’s
Omicron BA.5 challenge agent was successfully completed in 2023.

**Highlights**

| • | Characterisation study to establish world’s first Omicron BA.5 challenge model | 
| • | Study to utilise hVIVO’s new state-of-the-art containment level 3 (CL3) quarantine facilities in Canary Wharf | 
| • | FluCamp to recruit healthy 18-30 year old seropositive volunteers who have previously completed a course of COVID-19 vaccination | 
| • | New quarantine unit in Canary Wharf facilitates the expansion of hVIVO’s world leading portfolio of human challenge models |

The Study aims to identify a dose of hVIVO’s Omicron BA.5 challenge agent that establishes
a safe, measurable and reproducible disease in healthy volunteers with sufficiently
high infection rates to then be able to use the model to test the efficacy of antivirals
and vaccines in the future. The Company’s dedicated volunteer recruitment arm, [FluCamp](https://flucamp.com/),
will recruit healthy volunteers aged 18-30 years who have previously received a 
full course of a licenced COVID-19 vaccine. Characterisation studies offer numerous
benefits to biopharma clients, including insights into specific pathogens that are
more precise, actionable, and relevant to support and refine vaccine or antiviral
development. They also provide the necessary data from which to design subsequent
antiviral or vaccine efficacy testing studies.

The Study is expected to commence in Q4 2024, with the majority of revenue recognised
in 2025, and will take place at the Company’s new CL3 quarantine facility at Canary
Wharf. hVIVO’s facility has been specifically designed to meet the highest hospital
isolation suite standards suitable for CL3 pathogens and is equipped with advanced
safety features including physical containment barriers, controlled ventilation 
systems with negative pressure and HEPA filtration, and comprehensive waste management
protocols. This is the first COVID-related work that hVIVO will be undertaking since
the manufacture of the Omicron BA.5 challenge agent.

Dependent on the successful completion of the characterisation study and receipt
of relevant regulatory approvals, the Company expects to conduct multiple Omicron
human challenge trials to test the efficacy of medical products from mid-2025. hVIVO
successfully conducted the world’s first SARS-CoV-2 characterisation study, using
the original COVID-19 strain in 2021, with data showing that SARS-CoV-2 human challenge
studies are safe in healthy young adults.

> **Yamin ‘Mo’ Khan, Chief Executive Officer, said:** _“One of our key goals at 
> hVIVO is to further diversify our challenge trial offerings. The establishment
> of a COVID challenge model is a key step to penetrating a new and expanding market,
> especially with regards to mucosal and multi-valent COVID vaccine development.
> This study will take place at our new CL3 quarantine facility in Canary Wharf,
> which will open shortly. The new site, which was largely funded by a number of
> key clients, is the largest human challenge trial quarantine clinic in the world
> and is highly specialised in its design to facilitate the safe conduct of challenge
> studies. Securing this contract further validates the move to our new facilities
> and the new opportunities it brings for CL3 category projects.”_

> **Dr Andrew Catchpole, Chief Scientific Officer of hVIVO, said:** _“We are excited
> to begin work on characterising our Omicron challenge agent, which has been made
> possible by our new CL3 facilities in Canary Wharf. We have leading expertise 
> in characterising SARS-CoV-2 challenge agents, having successfully conducted the
> world’s first COVID-19 characterisation study. The client funding towards this
> study demonstrates the strong interest and growing pipeline in this indication
> due to the continued risk that COVID-19, and particularly the Omicron strain, 
> poses to global health and ongoing need for improved vaccines and treatments.”_

Share on:
